Epithalon and MOTS-C both target aging — but they address different hallmarks with fundamentally different mechanisms. Understanding which hallmark your research targets determines which compound is appropriate.

Epithalon's approach: The cellular division clock. Every cell division shortens telomeres. When telomeres reach critical length, the cell enters senescence. Epithalon reportedly reactivates telomerase to extend telomeres, potentially resetting this clock. It targets the countdown timer itself.

MOTS-C's approach: The cellular energy infrastructure. Mitochondria produce less energy, generate more waste (ROS), and communicate less effectively with the nucleus as they age. MOTS-C activates AMPK — the same metabolic switch that exercise activates — potentially restoring mitochondrial function and metabolic health. It targets the power plant.

These are different levels of biology. Telomere attrition limits how many times a cell can divide. Mitochondrial dysfunction limits how well a cell functions between divisions. Both contribute to aging, but through independent mechanisms.

Epithalon: Consistent findings across multiple publications from Khavinson's group. Telomerase activation in cell culture, melatonin restoration in aged animals, lifespan extension in rodent models. Primary limitation: limited independent replication. The data is internally consistent but awaits broader validation.

MOTS-C: Newer compound with rapidly growing evidence. AMPK activation well-established. Exercise connection validated (MOTS-C levels rise during exercise in humans). Mouse metabolic improvements documented. Primary limitation: also concentrated in one primary laboratory (Lee at USC), though independent work is emerging faster than for Epithalon.

Choose Epithalon if: Your research focuses on telomere biology, cellular replicative lifespan, telomerase enzymology, pineal gland/melatonin biology, or the replicative senescence hallmark of aging.

Choose MOTS-C if: Your research focuses on mitochondrial function, exercise physiology, AMPK signaling, metabolic aging, or the mitochondrial dysfunction hallmark of aging.

Choose both if: Your protocol studies multi-hallmark interventions — investigating whether simultaneously addressing telomere attrition and mitochondrial dysfunction produces effects beyond single-hallmark intervention.